Expert opinion on therapeutic targetsJun 15, 2026

How SIRT1 helps protect the heart and blood vessels and its possible treatments

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 19, 2026

Abstract

SIRT1 influences cardiovascular disease development by regulating inflammation, immune responses, oxidative stress, and autophagy.

The SIRT family includes seven proteins, with SIRT1 playing a crucial role in cardiovascular health.
SIRT1 activators like resveratrol and SRT1720 have shown preclinical efficacy in addressing cardiovascular conditions.
Challenges in clinical translation of SIRT1 activators include issues of dose dependency and specificity.
Identifying predictive biomarkers may help enhance the therapeutic potential of SIRT1-targeted interventions.
Future clinical trials should focus on establishing the safety and effectiveness of therapies targeting SIRT1.

Simplified

INTRODUCTION: Cardiovascular diseases (CVDs) pose a significant threat to the health of middle-aged and elderly people. They are widely recognized as a major public health concern. The sirtuin (SIRT) family comprises seven proteins (SIRT1-SIRT7), all of which contain a highly conserved nicotinamide adenine dinucleotide (NAD)-binding catalytic domain. Notably, SIRT1 influences the development and progression of CVDs by regulating biological processes such as inflammation, immune responses, oxidative stress, and autophagy. +

AREAS COVERED: This review summarizes the biological functions of SIRT1 and its role in major cardiovascular conditions, with particular attention to cell-type-specific effects. It examines the preclinical efficacy of SIRT1 activators, such as resveratrol and SRT1720, and discusses challenges including dose dependency, specificity, and barriers to clinical translation. A comprehensive literature search (PubMed, Web of Science, Scopus; 2000-April 2026) was conducted to identify studies on SIRT1 in CVDs, with a focus on mechanistic insights and therapeutic relevance.

EXPERT OPINION: We believe that developing highly specific SIRT1 activators, identifying predictive biomarkers, and elucidating tissue-selective regulatory mechanisms can amplify SIRT1's protective effects in cardiac diseases. Current and future clinical trials should establish the safety and efficacy of SIRT1-targeted therapies at the earliest possible stage.

Full Text

Full text is available at the source.

View Full Text ↗

How SIRT1 helps protect the heart and blood vessels and its possible treatments

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief